The US Food and Drug Administration granted Luye Pharma Group (HKG:2186) marketing approval for its LY03010 injectable suspension for adult schizophrenia patients, according to a Sunday filing with the Hong Kong Stock Exchange.
The drug is also indicated for patients with schizoaffective disorder as a sole therapy and as a supplement to mood stabilizers or antidepressants, the filing said.
Luye Pharma Group shares were up 1% recently.
Price (HKD): $2.80, Change: $+0.03, Percent Change: +1.08%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments